BRAF V600 Mutation Detection in Plasma Cell-Free DNA: NCCTG N0879 (Alliance)

In advanced melanoma, detectable cfDNA V600E/K mutation is present in about half the patients with stage IV with -mutant melanoma tumor tissue and appears to confer a poorer prognosis when detectable. Given the poorer prognosis, cfDNA can be used to risk-stratify patients with metastatic melanoma in practice or clinical trials. clinicaltrials.gov Identifier: NCT00976573.